{
    "Trade/Device Name(s)": [
        "Aperio ePathology eIHC IVD System",
        "AT Turbo",
        "CS2"
    ],
    "Submitter Information": "Leica Biosystems Imaging, Inc.",
    "510(k) Number": "K141109",
    "Predicate Device Reference 510(k) Number(s)": [
        "K071128",
        "K073677"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "NOT",
        "NQN"
    ],
    "Summary Letter Date": "April 29, 2014",
    "Summary Letter Received Date": "April 30, 2014",
    "Submission Date": "April 28, 2014",
    "Regulation Number(s)": [
        "21 CFR 864.1860"
    ],
    "Regulation Name(s)": [
        "Immunohistochemistry reagents and kits"
    ],
    "Analyte Class(es)": [
        "anatomic pathology"
    ],
    "Analyte(s)": [
        "HER2/neu (c-erbB-2)",
        "Estrogen Receptor (ER)",
        "Progesterone Receptor (PR)"
    ],
    "Specimen Type(s)": [
        "Formalin-fixed, paraffin-embedded neoplastic tissue"
    ],
    "Specimen Container(s)": [
        "Glass microscope slide"
    ],
    "Instrument(s)/Platform(s)": [
        "Aperio ePathology eIHC IVD System",
        "ScanScope AT Turbo",
        "ScanScope CS2",
        "eSlideManager software",
        "ImageScope"
    ],
    "Method(s)/Technology(ies)": [
        "Digital slide scanning",
        "Image analysis",
        "Colorimetric pattern recognition",
        "Morphometric pattern recognition"
    ],
    "Methodologies": [
        "Computer-assisted image analysis",
        "Immunohistochemistry (IHC)",
        "Digital pathology information management"
    ],
    "Submission Type(s)": [
        "System",
        "Analyzer",
        "Software",
        "Accessory"
    ],
    "Document Summary": "FDA 510(k) summary for Aperio ePathology eIHC IVD System for digital pathology-based automated image analysis of IHC slides in breast cancer diagnosis and therapy guidance",
    "Indications for Use Summary": "Automated digital slide creation, management, viewing, and analysis system for in vitro diagnostic use aiding pathologists in detecting, counting, and classifying tissues and cells; HER2/neu application aids assessment for Herceptin\u00ae treatment; ER/PR applications aid management, prognosis, and prediction of breast cancer therapy outcomes",
    "fda_folder": "Hematology"
}